Literature DB >> 10683860

MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons.

N W Kowall1, P Hantraye, E Brouillet, M F Beal, A C McKee, R J Ferrante.   

Abstract

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity reproduces many of the features of Parkinson's disease (PD). alpha-Synuclein has been identified as a prominent component of the Lewy body (LB), the pathological hallmark of PD. MPTP-treated primates have been reported to develop intraneuronal inclusions but not true Lewy bodies. We administered MPTP to baboons and used a monoclonal alpha-synuclein antibody to define the relationship between neuronal degeneration and alpha-synuclein immunoreactivity in the substantia nigra. MPTP-induced neuronal degeneration was associated with the redistribution of alpha-synuclein from its normal synaptic location to aggregates in degenerating neuronal cell bodies. alpha-Synuclein aggregation induced by MPTP models the early stages of Lewy body formation and may be a fundamental step in the evolution of neuronal degeneration in PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683860     DOI: 10.1097/00001756-200001170-00041

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  70 in total

1.  Neuropathology in mice expressing human alpha-synuclein.

Authors:  H van der Putten; K H Wiederhold; A Probst; S Barbieri; C Mistl; S Danner; S Kauffmann; K Hofele; W P Spooren; M A Ruegg; S Lin; P Caroni; B Sommer; M Tolnay; G Bilbe
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.

Authors:  Souvarish Sarkar; Hai M Nguyen; Emir Malovic; Jie Luo; Monica Langley; Bharathi N Palanisamy; Neeraj Singh; Sireesha Manne; Matthew Neal; Michelle Gabrielle; Ahmed Abdalla; Poojya Anantharam; Dharmin Rokad; Nikhil Panicker; Vikrant Singh; Muhammet Ay; Adhithiya Charli; Dilshan Harischandra; Lee-Way Jin; Huajun Jin; Srikant Rangaraju; Vellareddy Anantharam; Heike Wulff; Anumantha G Kanthasamy
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  Neuroprotective upregulation of endogenous α-synuclein precedes ubiquitination in cultured dopaminergic neurons.

Authors:  R E J Musgrove; A E King; T C Dickson
Journal:  Neurotox Res       Date:  2010-07-09       Impact factor: 3.911

4.  Combination therapy in a transgenic model of Alzheimer's disease.

Authors:  Bruce G Jenkins; Alpaslan Dedeoglu; Nurgul Aytan; Ji-Kyung Choi; Isabel Carreras; Neil W Kowall
Journal:  Exp Neurol       Date:  2013-10-10       Impact factor: 5.330

Review 5.  Epigenetic regulation in Parkinson's disease.

Authors:  Catherine Labbé; Oswaldo Lorenzo-Betancor; Owen A Ross
Journal:  Acta Neuropathol       Date:  2016-06-29       Impact factor: 17.088

Review 6.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 7.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

8.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

Review 9.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.